ArticleBMC pregnancy and childbirth2026
Mechanisms of vaginal bacteria-induced fetal membrane damage and tocilizumab's therapeutic potential in PPROM.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThis study investigates the deleterious effects of vaginal opportunistic pathogens on fetal membranes and evaluates the therapeutic potential of tocilizumab (TCZ), an interleukin-6 (IL-6) receptor antagonist, in attenuating these effects, aiming to improve strategies for the prevention and treatment of preterm prelabor rupture of membranes (PPROM).
methodsBioinformatics analyses were conducted to identify inflammatory pathways associated with PPROM. Clinical specimens, including placental tissue and peripheral blood samples, were collected postpartum. Placental pathology was performed to assess the incidence of histological chorioamnionitis. Peripheral blood levels of IL-6 were quantified using enzyme-linked immunosorbent assay (ELISA). The expression of phosphorylated JAK2 and STAT3, key components of the JAK-STAT signaling pathway, in fetal membrane tissues was examined by Western blotting. Immunohistochemistry (IHC) was employed to detect the expression and localization of matrix metalloproteinase-9 (MMP-9) and its tissue inhibitor-1 (TIMP-1) in placental tissues. For in vitro experiments, a co-culture model incorporating bacteria and fetal membrane-derived WISH cells was established to evaluate the effects of bacterial infection on cell viability and apoptosis. Subsequently, IL-6 levels in the cell supernatants were measured. Western blotting was used to detect the activation of the JAK-STAT pathway in bacterially infected WISH cells, and immunocytochemistry (ICC) was performed to assess the expression and localization of MMP-9 and TIMP-1. Finally, the modulatory effects of TCZ on bacterially infected WISH cells were analyzed.
resultsBioinformatics analysis identified inflammatory pathways, particularly the JAK-STAT pathway, as being associated with PPROM. Clinical samples revealed a higher incidence of clinic chorioamnionitis(CCA) in PPROM cases. Elevated peripheral plasma IL-6 levels were detected in individuals with PPROM, accompanied by increased phosphorylation of JAK2 and STAT3 in fetal membrane tissues, along with upregulated MMP-9 and downregulated TIMP-1 expression. In vitro, infection with Streptococcus agalactiae(S.agalactiae), Enterococcus faecalis(E. faecalis), or Escherichia coli (E.coli) significantly reduced WISH cell viability and induced apoptosis. Bacterial infection also led to markedly increased IL-6 levels in culture supernatants. In infected WISH cells, enhanced p-JAK2 and p-STAT3 were observed, together with elevated MMP-9 and reduced TIMP-1 expression. TCZ treatment reduced IL-6 levels. It inhibited JAK2 and STAT3 phosphorylation in fetal membrane tissues. MMP-9 expression was downregulated, and TIMP-1 expression was restored.
conclusionsVaginal opportunistic pathogens contribute to PPROM by compromising fetal membrane integrity through activation of inflammatory pathways such as JAK-STAT, disruption of the MMP-9/TIMP-1 balance, reduction of cell viability, and induction of apoptosis. TCZ, by targeting the IL-6 signaling axis, demonstrates potential to intervene in this pathological process, offering a promising therapeutic strategy for the prevention and treatment of PPROM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.